Costs of radium-223 and the pharmacy preparation ¹⁷⁷Lu-PSMA-I&T for metastatic castration-resistant prostate cancer in Dutch hospitals

References

• IKNL Nederland. [Prostate cancer in the Netherlands] [Internet]. 2022. [cited 2022 Dec 1]. Available from: https://iknl.nl/prostaatkanker-in-nederland.
   Google Scholar
• Zorginstituut Nederland. Verbetersignalement Zinnig gebruik van geneesmiddelen bij patiënten met castratie refractair prostaatcarcinoom [Improvement report Sensible use of medicines patients with castration refractory prostate carcinoma] [Internet]. 2016. [cited 2022 Dec 1]. Available from: https://www.zorginstituutnederland.nl/werkagenda/publicaties/rapport/2016/11/21/zinnige-zorg-verbetersignalement-zinnig-gebruik-van-geneesmiddelen-bij-patienten-met-castratie-refractair-prostaatcarcinoom.
   Google Scholar
• Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65:1180–1192.
   PubMed Web of Science ®Google Scholar
• Ivanescu C, Phung D, Loriot Y, et al. Skeletal-related events (SRES) impact significantly the health-related quality of life (HRQOL) of chemo-naive men with metastatic castration resistant prostate cancer (MCRPC). Value in Health. 2014;17:A650–A651.
   PubMed Web of Science ®Google Scholar
• Sraieb M, Hirmas N, Conrad R, et al. Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [223Ra]RaCl2 therapy. Medicine. 2020;99:e22287.
   PubMed Web of Science ®Google Scholar
• VZInfo. Zorguitgaven prostaatkanker naar sector 2019 [Prostate cancer health care expenditure by sector 2019] [Internet]. [cited 2022 Oct 7]. Available from: https://www.vzinfo.nl/prostaatkanker/zorguitgaven.
   Google Scholar
• He L, Fang H, Chen C, et al. Metastatic castration-resistant prostate cancer: academic insights and perspectives through bibliometric analysis. Medicine (Baltimore). 2020; 99:e19760.
   PubMed Web of Science ®Google Scholar
• European Association of Urology. Guidelines on prostate cancer [Internet]. 2022. [cited 2023 Feb 14]. Available from: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-EANM-ESTRO-ESUR-ISUP_SIOG-Guidelines-on-Prostate-Cancer-2022_2022-04-25-063938_yfos.pdf.
   Google Scholar
• European Medicines Agency (EMA). Summary of product characteristics (SmPC) radium-223. 2013 [cited 2023 Jan 5]. Available from: https://www.ema.europa.eu/en/documents/product-information/xofigo-epar-productinformation_en.pdf
   Google Scholar
• de Klerk J, ter Heine R, Bloemendaal H. Richtlijn 89Sr chloride (Metastron®) [Guideline Richtlijn 89Sr chloride (Metastron®)] [Internet]. [cited 2022 Dec 6]. Available from: https://richtlijnendatabase.nl/gerelateerde_documenten/f/17268/89Sr%20Chloride.pdf
   Google Scholar
• Liepe K, Kropp J, Runge R, et al. Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases. Br J Cancer. 2003;89:625–629.
   PubMed Web of Science ®Google Scholar
• Petersen LL, Lund L, Jonler M, et al. Samarium-153 treatment of bone pain in patients with metastatic prostate cancer. Dan Med Bull. 2010;57:A4154.
   PubMedGoogle Scholar
• Z-index 177Lu-PSMA-I&T (16995740). 2022.
   Google Scholar
• Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. New Eng J Med. 2013;369:213–223.
   PubMed Web of Science ®Google Scholar
• Z-Index Radium-223 (16225643).
   Google Scholar
• Sartor O, de Bono J, Chi KN, et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. New Eng J Med. 2021;385:1091–1103.
   PubMed Web of Science ®Google Scholar
• Heidegger I, Kesch C, Kretschmer A, et al. Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review. Ther Adv Med Oncol. 2022;14:17588359221081922.
   Web of Science ®Google Scholar
• Novartis. Novartis receives European Commission approval for Pluvicto® as the first targeted radioligand therapy for treatment of progressive PSMA–positive metastatic castration-resistant prostate cancer [Internet]. 2022. [cited 2023 Jan 5]. Available from: https://www.novartis.com/news/media-releases/novartis-receives-european-commission-approval-pluvicto-first-targeted-radioligand-therapy-treatment-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer.
   Google Scholar
• BS Health Consultancy. Toelatingslandschap Geneesmiddelen Nederland: hoepels & knelpunten [Licensing landscape Medicines Netherlands: hoops & bottlenecks]. 2020.
   Google Scholar
• Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT 2002. Therapy after second-line hormonal treatment (SPLASH). [cited 2022 Oct 7]; Available from: https://clinicaltrials.gov/ct2/show/NCT04647526.
   Google Scholar
• Martini A, Mottet N, Montorsi F, et al. A plea for economically sustainable evidence-based guidelines. Eur Urol. 2022;82:449–451.
   PubMed Web of Science ®Google Scholar
• Meander Hospital. Lutetium-177-PSMA-therapie [Lutetium-177-PSMA-therapy] [Internet]. [cited 2022 Dec 1]. Available from: https://www.meandermc.nl/zorg/behandelingen-onderzoeken/lutetium-177-psma-uitzaaiingen-prostaatkanker/.
   Google Scholar
• ErasmusMC. Productievergunning voor nieuw radioactief geneesmiddel [Production licence of new radioactive medication] [Internet]. 2021. Available from: https://amazingerasmusmc.nl/radiologie/productievergunning-voor-nieuw-radioactief-geneesmiddel/.
   Google Scholar
• Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Med. 2022;20:23.
   PubMed Web of Science ®Google Scholar
• Stichting Dutch Ur-Oncology studygroup (DUOS). Uitkomst VISION -177Lutetium-PSMA-617 (177Lu-PSMA)- helaas geen grote vooruitgang [Outcome VISION -177Lutetium-PSMA-617 (177Lu-PSMA)- unfortunately no major progress] [Internet]. 2021. [cited 2023 Jan 30]. Available from: https://stichtingduos.nl/top-5-meest-gelezen-nieuwsberichten-stichting-duos-juni-2021/.
   Google Scholar
• Zorginstituut Nederland. Guideline for economic evaluations in healthcare [Internet]. 2016. [cited 2020 Dec 1]. p. 1–45. Available from: https://english.zorginstituutnederland.nl/publications/reports/2016/06/16/guideline-for-economic-evaluations-in-healthcare.
   Google Scholar
• Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
   Google Scholar
• NVNG NN, NVKF, NVS, et al. Blootstelling van derden bij therapie met 177Lu [Third party exposure in therapy with 177Lu] [Internet]. [cited 2022 Dec 1]. Available from: https://richtlijnendatabase.nl/richtlijn/therapeutische_doses_radionucliden/blootstelling_van_derden_bij_therapie_met_177lu.html#:∼:text=Indien%20op%20basis%20van%20het,blijft%2C%20kan%20ontslag%20eerder%20plaatsvinden.
   Google Scholar
• OpenDIS data. [cited 2023 Jan 5]. Available from: opendisdata.nl
   Google Scholar
• Dutch statistics (CBS). Consumer price index [Internet]. [cited 2022 Dec 1]. Available from: https://opendata.cbs.nl/statline/#/CBS/nl/dataset/83131ned/table?fromstatweb.
   Google Scholar
• Peters ML, de Meijer C, Wyndaele D, et al. Dutch economic value of radium-223 in metastatic Castration-Resistant prostate cancer. Appl Health Econ Health Policy. 2018;16:133–143.
   PubMed Web of Science ®Google Scholar
• Hakkaart-van Roijen L, van der Linden N, Bouwmans C, et al. Kostenhandleiding: Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg. [Cost manual: Methodology of cost studies and reference prices for health care economic evaluations.] Dutch National Health Care Institute. 2016;1–73. [cited 2023 Jan 5]. Available from: https://www.zorginstituutnederland.nl/over-ons/werkwijzen-en-procedures/adviseren-over-en-verduidelijkenvan-het-basispakket-aan-zorg/beoordeling-van-geneesmiddelen/richtlijnen-voor-economische-evaluatie.
   Google Scholar
• Nederlandse Zorgautoriteit (NZA). Kostprijsaanlevering add-on/ozp apotheekbereiding [Cost price delivery add-on/ozp pharmacy preparation] [Internet]. [cited 2023 Jan 24]. Available from: https://puc.overheid.nl/nza/doc/PUC_628654_22/1/.
   Google Scholar
• Erasmus MC. Tarieven ODV per 1 maart 2021 [Tarriffs ODV per 1 March 2021]. [Internet]. 2021 [cited 2022 Dec 1]. Available from: Erasmusmc.nl.
   Google Scholar
• Antoni van Leeuwenhoek. Passantenprijslijst DBC zorgproducten en overige zorgproducten 2021 [Passantenprijslijst DBC zorgproducten en overige zorgproducten 2021] [Internet]. [cited 2022 Dec 1]. Available from: https://www.avl.nl/media/4346/passantenprijzen-zorgproducten-avl-2021-versie-tbv-publicatie.pdf.
   Google Scholar
• Nederlandse Zorgautoriteit (NZA). Tarieven diagnostisch onderzoek [Tarrifs diagnostic screening] [Internet]. 2020. [cited 2020 Dec 10]. Available from: https://puc.overheid.nl/nza/doc/PUC_21659_22/1/.
   Google Scholar
• Nederlandse Zorg authoriteit. Overzicht wijzigingsverzoeken medisch-specialistische zorg [Overview of change requests for specialist medical care] [Internet]. 2022. [cited 2022 Nov 24]. Available from: https://puc.overheid.nl/nza/doc/PUC_259733_22/1/.
   Google Scholar
• Utrecht UMC. Behandeling prostaatkanker met Lutetium-177-PSMA [Treatment prostate cancer with Lutetium-177PSMA] [Internet]. [cited 2022 Dec 2]. Available from: https://www.umcutrecht.nl/nl/behandeling/behandeling-prostaatkanker-met-lutetium-177-psma.
   Google Scholar
• Radboud UMC. Behandeling met radioactief lutetium-177-PSMA [Treatment with radioactive Lutetium-177-PSMA] [Internet]. [cited 2022 Oct 24]. Available from: https://www.radboudumc.nl/patientenzorg/behandelingen/behandeling-met-radioactief-lutetium-177-psma.
   Google Scholar
• Horizonscan. 177Lu-PSMA-617 [Internet]. 2021. [cited 2022 Oct 24]. Available from: https://www.horizonscangeneesmiddelen.nl/geneesmiddelen/lutetium-177lu-vipivotide-tetraxetan-oncologie-prostaatkanker/versie2?lang=nl.
   Google Scholar
• National Institute for Health and Care Excellence [NICE]. Lu vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [Internet]. 2022. Available from: https://www.nice.org.uk/guidance/indevelopment/gid-ta10730.
   Google Scholar
• Omar MI, Roobol MJ, Ribal MJ, et al. Introducing PIONEER: a project to harness big data in prostate cancer research. Nat Rev Urol. 2020;17:351–361.
   PubMed Web of Science ®Google Scholar
• Kuppen MCP, Westgeest HM, van der Doelen MJ, et al. Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer. Future Oncol. 2020;16:1371–1384.
   PubMed Web of Science ®Google Scholar
• Meander hospital. Ontwikkeling van radioactief geneesmiddel Lutetium [Development of radioactive medication Lutetium] [Internet]. [cited 2022 Oct 24]. Available from: https://www.meandermc.nl/zorg/specialismen-afdelingen/apotheek/top-10-innovaties-2021/ontwikkelling-van-radioactief-geneesmiddel-lutetium/
   Google Scholar